1. Home
  2. BNR

as of 04-02-2026 4:00pm EST

$16.20
$0.10
-0.61%
Stocks Health Care Medical Specialities Nasdaq

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Founded: 2014 Country:
China
China
Employees: N/A City: N/A
Market Cap: 252.7M IPO Year: 2019
Target Price: N/A AVG Volume (30 days): 31.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.18 - $41.72 Next Earning Date: 03-12-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 111.65% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered BNR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 70.89%
70.89%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Burning Rock Biotech Limited (BNR)

Han Yusheng

Director

Buy
BNR Mar 31, 2026

Avg Cost/Share

$17.36

Shares

314,870

Total Value

$5,466,143.20

Owned After

17,672,676

SEC Form 4

Share on Social Networks: